| Name | Remacemide hydrochloride | CAS# | 111686-79-4 | |
|---|---|---|---|---|
| Price | ¥Inquiry/1g | Purity | 98.9% | |
| Stocking Period |
1 Day | Stock | In Stock |
| Detail
Product Information
Remacemide, also known as PR-934423 and FPL 12924AA, is a low-affinity NMDA antagonist with sodium channel blocking properties. It has been studied for the treatment of acute ischemic stroke, epilepsy, Huntington's disease, and Parkinson's disease. Remacemide binds weakly and noncompetitively to the ionic channel site of the NMDA receptor complex. Remacemide binds both allosterically and in the channel. However, because remacemide binds so weakly to NMDAR, much of remacemide's in vivo effect against excitotoxicity is thought to be caused by its metabolic transformation to the more potent desglycine derivative FPL 12495. |